16-hydroxyhexadecanoic acid allyl ester | 275808-63-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 16-hydroxyhexadecanoic acid allyl ester
• 英文别名: allyl 16-hydroxyhexadecanoate；Prop-2-enyl 16-hydroxyhexadecanoate
• CAS: 275808-63-4
• 化学式: C₁₉H₃₆O₃
• 分子量: 312.493
• InChiKey: XEYXZVRTTMNQRP-UHFFFAOYSA-N

物化性质

• 沸点：
  410.5±18.0 °C(Predicted)
• 密度：
  0.923±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  22
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  16-hydroxyhexadecanoic acid allyl ester 在 4-二甲氨基吡啶 、 2,6-二叔丁基吡啶 、 草酰氯 、 乙酸吗啉 、 4-甲基苯磺酸吡啶 、 溶剂黄146 、 二甲基亚砜 、 sodium sulfate 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 120.5h， 生成 (3R,4R,4aR,6'R,7S)-4-[15-(allyloxycarbonyl)pentadecyloxycarbonyl]-3,4,4a,5,6,7-hexahydro-1-methoxy-7-(2-oxoethyl)pyrrolo[1,2-c]pyrimidine-3-spiro-2'-(6'-methyl)-3',4',5',6'-tetrahydro-2H-pyran
  参考文献：
  名称：

  胍类生物碱 Crambescidin 家族的实用入门。Ptilomycalin A、Crambescidin 657 及其甲酯（Neofolitispates 2）和 Crambescidin 800 的对映选择性全合成

  摘要：

  在结构上最显着的胍天然产物是海藻西丁/ptilomycalin A 家族的海洋生物碱。描述了用于制备在 C13 处缺乏氧化的具有药理学意义的 crambescidin/ptilomycalin A 生物碱的实用策略的演变。详细报道了 crambescidin 800 (2)、crambescidin 657 (6) 和 neofolitispate 2 (7) 的首次全合成。这些收敛全合成的核心战略步骤是 β-酮酯 24 与脲基氨基 61 的系链 Biginelli 缩合，以结合胍核的所有碳并设置关键的 C10-C13 立体关系。crambescidin 800 (2) 的全合成以 3% 的总产率从市售的 3-butyn-1-ol 中通过 16 个分离和纯化的中间体完成。还提供了我们早期的 ptilomycalin A (1) 全合成的全部细节。本公开内容中描述的总合成证实了 1、2、6 和

  DOI：

  10.1021/ja000234i
• 作为产物：
  描述：

  16-羟基棕榈酸 、 烯丙醇 在 硫酸 作用下， 反应 6.0h， 以61%的产率得到16-hydroxyhexadecanoic acid allyl ester
  参考文献：
  名称：

  Design, Synthesis, and Antibacterial Properties of Dual-Ligand Inhibitors of Acetyl-CoA Carboxylase

  摘要：

  There is an urgent demand for the development of new antibiotics due to the increase in drug-resistant pathogenic bacteria. A novel target is the multifunctional enzyme acetyl-CoA carboxylase (ACC), which catalyzes the first committed step in fatty acid synthesis and consists of two enzymes: biotin carboxylase and carboxyltransferase. Covalently attaching known inhibitors against these enzymes with saturated hydrocarbon linkers of different lengths generated dual-ligand inhibitors. Kinetic results revealed that the dual-ligands inhibited the ACC complex in the nanomolar range. Microbiology assays showed that the dual-ligand with a 15-carbon linker did not exhibit any antibacterial activity, while the dual-ligand with a 7-carbon linker displayed broad-spectrum antibacterial activity as well as a decreased susceptibility in the development of bacterial resistance. These results suggest that the properties of the linker are vital for antibacterial activity and show how inhibiting two different enzymes with the same compound increases the overall potency while also impeding the development of resistance.

  DOI：

  10.1021/jm501082n

文献信息

• Total Synthesis and Properties of the Crambescidin Core Zwitterionic Acid and Crambescidin 359
  作者：Zachary D. Aron、Larry E. Overman

  DOI：10.1021/ja042875+

  日期：2005.3.1

  carboxylate 9 was shown to readily decarboxylate to form crambescidin 359 (8). Decarboxylation of crambescidin core acid 9 was fastest under basic conditions. In the presence of base, up to eight deuterium atoms can be incorporated into the pentacyclic crambescidin core. Both deuterium incorporation and decarboxylation of crambescidin core acid 9 are the result of facile ring opening of the spirocyclic ether

  描述了 crambescidin 核心酸 9、crambescidins 359 (8) 和 431 (7) 的全合成，以及 crambescidin 核心的性质。羧酸胍 9 合成路线的一个关键步骤是 Pd(0) 催化裂解五环肉桂酯 15 的酯侧链。该酯还用于制备 C14 侧链不同的小海蜇素生物碱类似物库. 两性离子胍羧酸盐 9 很容易脱羧形成海贝西丁 359 (8)。在碱性条件下，crambescidin core acid 9 的脱羧速度最快。在碱的存在下，多达八个氘原子可以结合到五环 crembescidin 核心中。
• Method for improved chemical synthesis of guanidinium alkaloids
  申请人：Overman E. Larry

  公开号：US20050239804A1

  公开（公告）日：2005-10-27

  Improved methods for convergent, total enantioselective synthesis of guanidinium alkaloid compounds including ones having cis- or -trans-1-oxo-and 1-iminohexahydropyrrolo [1,2c]pyrimidine units including, 13,14,15-isocrambescidin 800, crambescidin 800 and ptilomycalin A, for use as therapeutic agents having antifungal and/or antiviral and/or antitumor activity are provided. Methods for preparing novel pentacyclic intermediates for the preparation of the crambescidin/ptilomycalin family of guanidinium alkaloids and congeners are also disclosed.

  提供了改进的方法，用于收敛、完全对映选择性合成葫芦啶生物碱化合物，包括具有顺式或反式1-氧基和1-亚氨基六氢吡咯并[1,2c]嘧啶单元的化合物，包括13,14,15-异克林贝斯酸800、克林贝斯酸800和莫纳霉素A，用作具有抗真菌和/或抗病毒和/或抗肿瘤活性的治疗剂。还公开了制备新的五环中间体的方法，用于制备克林贝斯酸/莫纳霉素家族的葫芦啶生物碱及其同系物。
• Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
  申请人：McDaniel C. Steven

  公开号：US20100210745A1

  公开（公告）日：2010-08-19

  Disclosed herein are polymeric materials such as a coating, a plastic, a laminate, a composite, an elastomer, an adhesive, or a sealant; a surface treatment such as a textile finish or a wax; a filler for such a polymeric material or a surface treatment that includes an enzyme such as an esterase (e.g., a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme), an enzyme (e.g., a lysozyme, a lytic transglycosylase) that degrades a cell wall and/or a cell membrane component, a biocidal or biostatic peotide, and/or a peptidase. Also disclosed herein are methods of altering a material's property such as service life, flexability, or rigidity, by incorporation of an enzyme into a material capable of being chemically crosslinked by the activity of a lipolytic enzyme, a hydrolase, and/or a urease.

  本文公开了一些聚合材料，如涂层、塑料、层压板、复合材料、弹性体、粘合剂或密封剂；一种表面处理，如纺织品涂层或蜡；一种填料，用于这样的聚合材料或表面处理，其中包括一种酶，如酯酶（例如，脂肪水解酶，硫酸酯水解酶，有机磷化合物降解酶），降解细胞壁和/或细胞膜成分的酶（例如，溶菌酶，裂解转糖基酶），生物杀菌或生物静态肽，以及/或肽酶。本文还公开了通过将酶纳入可通过脂肪水解酶、水解酶和/或脲酶的活性交联材料中来改变材料性能，如使用寿命、柔韧性或刚度的方法。
• Anti-fouling Paints and Coatings
  申请人：Reactive Surfaces LTD

  公开号：US20150191607A1

  公开（公告）日：2015-07-09

  Disclosed herein are polymeric materials such as a coating, a plastic, a laminate, a composite, an elastomer, an adhesive, or a sealant; a surface treatment such as a textile finish or a wax; a filler for such a polymeric material or a surface treatment that includes an enzyme such as an esterase (e.g., a lipolytic enzyme, a sulfuric ester hydrolase, an organophosphorus compound degradation enzyme), an enzyme (e.g., a lysozyme, a lytic transglycosylase) that degrades a cell wall and/or a cell membrane component, a biocidal or biostatic peptide, and/or a peptidase. Also disclosed herein are methods of altering a material's property such as service life, flexability, or rigidity, by incorporation of an enzyme into a material capable of being chemically crosslinked by the activity of a lipolytic enzyme, a hydrolase, and/or a urease.

  本文披露了聚合材料，例如涂层、塑料、层压材料、复合材料、弹性体、粘合剂或密封剂；表面处理，例如纺织品整理或蜡；填充剂，用于这种聚合材料或表面处理，包括酯酶（例如脂肪水解酶、硫酸酯水解酶、有机磷化合物降解酶）的酶，降解细胞壁和/或细胞膜成分的酶（例如溶菌酶、裂解转葡糖苷酶），生物杀菌或生物稳定肽，和/或肽酶。本文还披露了通过将酶并入能够通过脂肪水解酶、水解酶和/或脲酶的活性进行化学交联的材料中，改变材料性能（例如使用寿命、柔韧性或刚度）的方法。
• Method for preparing crambescidin core acid intermediates and their use for preparing crambescidin alkaloid analogs as therapeutic agents
  申请人：The Regents of the University of California

  公开号：US20030176697A1

  公开（公告）日：2003-09-18

  The invention provides methods to synthesize zwitterionic pentacyclic crambescidin core intermediates having the carboxylate side chain in the natural axial orientation, and a range of crambescidin alkaloid analogs.

  本发明提供了合成具有天然轴向羧酸侧链的齐聚物五环痉孪啶核心中间体以及一系列痉孪啶生物碱类似物的方法。